Li Yong, Wang Jun-jiang
Department of Gastrointestinal Surgery, Guangdong Academy of Medical Sciences, Guangzhou, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2011 Dec;31(12):2087-9.
To evaluate the clinical significance of blood and fecal expression of tumor M2-pyruvate kinase (Tumor M2-PK) in patients with colorectal cancer.
With 22 healthy subjects as controls, 44 patients with CRC were examined for tumor M2-PK in serum and fecal samples using a sandwich enzyme immunoassay.
The sensitivity of serum and fecal tumor M2-PK for detecting CRC was 59.1% and 63.6% with a specificity of 86.4% and 81.8%, respectively. The serum and fecal levels of tumor M2-PK showed a significant correlation in CRC patients.
Tumor M2-PK has good sensitivity and specificity in the diagnosis of CRC.
评估肿瘤M2丙酮酸激酶（Tumor M2-PK）在结直肠癌患者血液和粪便中的表达的临床意义。
以22名健康受试者作为对照，采用夹心酶免疫分析法对44例结直肠癌患者的血清和粪便样本进行肿瘤M2-PK检测。
血清和粪便肿瘤M2-PK检测结直肠癌的灵敏度分别为59.1%和63.6%，特异性分别为86.4%和81.8%。结直肠癌患者血清和粪便中肿瘤M2-PK水平呈显著相关。
肿瘤M2-PK在结直肠癌诊断中具有良好的灵敏度和特异性。
